NexMed, Inc. (NEXM), a developer of innovative transdermal products based on its proprietary NexACT drug delivery technology, announced that Health Canada has accepted the New Drug Submission (NDS) for its topical erectile dysfunction (ED) treatment for review. Health Canada's target is to complete review within three hundred (300) days for ninety percent (90 per cent) of submissions.

Vivian Liu, president and chief executive officer of NexMed, stated, "We are very pleased to reach another regulatory milestone. The acceptance of the NDS for review is a positive development for the discussions with potential commercialization partners in Canada."

NexMed, Inc. is leveraging its proprietary NexACT drug delivery technology to develop innovative topical pharmaceutical products that address unmet medical needs. NM100060, a novel onychomycosis treatment exclusively licensed to Novartis, is currently in pivotal Phase 3 trials in the US and Europe.